Clinical trials progression of anti-cancer effects exerted by zoledronic acid

Abstract

Abstract: Zoledronic acid, the third generation of nitrogen-containing bisphosphonate, is a potent inhibitor of osteoclastic bone resorption by inhibiting osteoclast activity and inducing osteoclast apoptosis and is currently approved for the treatment of tumor-induced hypercalcemia and the reduction and delay of skeletal complications in advanced bone-related malignancies. Data from preclinical studies of zoledronic acid suggest its definite anti-tumor effect. Recently, as several zoledronic acid related clinical trials are carried out, the anti-tumor effect of zoledronic acid attracts people's attention. These clinical trials show that zoledronic acid may improve treatment response of multiple myeloma, breast cancer, prostate cancer and lung cancer including prolonging the disease free survival (DFS) and overall survival (OS). However, some important questions remain, including optimal dosing, initiation and duration of therapy, to be studied in further investigations. Here, we summarized the potential role of zoledronic acid in cancer treatment.

Key words: Zoledronic acid, Anti-cancer, Clinical trials

CLC Number:

R73
R969.4

WANG Zeng, LU Hong-yang, WENG Lin. Clinical trials progression of anti-cancer effects exerted by zoledronic acid[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(8): 945-950.

References

[1] Delmas PD. The use of bisphosphonates in the treatment of osteoporosis[J]. Curr Opin Rheumatol, 2005, 17(4): 462- 466.
[2] Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates[J]. J Dent Res, 2007, 86(11): 1022-1033.
[3] Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J]. N Engl J Med, 2007, 356(18): 1809-1822.
[4] Henneman ZJ, Nancollas GH, Ebetino FH, et al. Bisphosphonate bone affinity as assessed by inhibition of carbonated apatite dissolution in vitro[J]. J Biomed Mater Res A, 2008, 85(4): 993-1000.
[5] Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients[J]. Clin Cancer Res, 2003, 9(8): 2893-2897.
[6] Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients[J]. J Interferon Cytokine Res, 2005, 25(3):144-151.
[7] Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases[J]. Nature, 2000, 407(6801): 249- 257.
[8] Boissier S, Colombel M, Delmas P, et al. Zoledronic acid inhibits in vivo experimental angiogenesis[J]. Bone, 2002, 30(3 Suppl):38S.
[9] Aviles A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma[J]. Med Oncol, 2007, 24(2): 227-230.
[10] Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma[J]. Cancer, 2008, 113(7):1588-1595.
[11] Morgan G, Child J, Gregory W, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial[J]. Lancet Oncol, 2011, 12(8):743-752.
[12] Okamoto K, Tsurutani J, Terashima M, et al. Zoledronic acid-induced regression of multiple metastases at nonskeletal sites[J]. Ann Oncol, 2009, 20(4): 796-797.
[13] Laggner U, Lopez JS, Perera G, et al. Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy[J]. Clin Immunol, 2009, 131(3): 367-373.
[14] Rack B, Juckstock J, Genss EM, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer[J]. Anticancer Res, 2010, 30(5): 1807-1813.
[15] Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial[J]. Lancet Oncol, 2010, 11(5): 421-428.
[16] Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premeno- pausal breast cancer[J]. N Engl J Med, 2009, 360(7): 679-691.
[17] Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial[J]. Lancet Oncol, 2011, 12(7): 631-641.
[18] Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study[J]. Ann Oncol, 2010, 21(11): 2188-2194.
[19] Brufsky A, Bosserman L, Caradonna R, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results[J]. Clin Breast Cancer, 2009, 9(2): 77-85.
[20] Coleman RE, Winter MC, Cameron D, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response; exploratory revidence for direct anti-tumour activity in breast cancer[J]. Br J Cancer, 2010, 102(7): 1099-1105.
[21] Ressler S, Mlineritsch B, Greil R. Zoledronic acid for adjuvant use in patients with breast cancer[J]. Expert Rev Anticancer Ther, 2011, 11(3): 333-349.
[22] Duchesne G, Woo H, Howell D, et al.Tribulations of a prostate cancer trial- lessons learned from TOAD, a cancer council victoria and transtasman radiation oncology group trial[J]. J Med Imaging Radiat Oncol, 2010, 54(5): 508-511.
[23] ClinicalTrials.gov. Postoperative use of zoledronic acid in breast cancer patients after neoadjuvant chemotherapy (NATAN)[EB/OL]. Available at: http://clinicaltrials.gov/ct2/show/NCT00512993 Accessed July 10, 2010.
[24] Wirth M, Tammela T, Debruyne F, et al. Effectiveness of zoledronic acid for the prevention of bone metastases in high-risk prostate cancer patients. A report of the ZEUS study [abstract 184] [R]. Presented at: 2008 Genitourinary Cancer Symposium; Feb ruary 14-16, 2008; San Francisco, CA.
[25] ClinicalTrials.gov. Zoledronate in preventing skeletal (bone)-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases[EB/OL]. Available at: http://clinicaltrials.gov/ct2/show/NCT00079001. Accessed July 10, 2010.
[26] Avilés A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma[J]. Med Oncol, 2007, 24(2): 227-30.
[27] Ozturk OH, Bozcuk H, Burgucu D, et al. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study[J]. Cell Biol Int, 2007, 31(9): 1069- 1071.
[28] Matsumoto S, Kimura S, Segawa H, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines[J]. Lung Cancer, 2005, 47(1): 31-39.
[29] Ory B, Heymann MF, Kamijo A, et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice[J]. Cancer, 2005, 104(11): 2522-2529.
[30] Mahtani R, Khan R, Jahanzeb M. The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer[J]. Clin Lung Cancer, 2011, 12(1): 26-32.
[31] Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis[J]. Int J Cancer, 2009, 125(7): 1705-1709.
[32] Pandya KJ, Gajra A, Warsi GM, et al. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer[J]. Lung Cancer, 2010, 67(3): 330-338.
[33] Scagliotti G, Manegold C, de Marinis F, et al. Evaluating the efficacy of zoledronic acid for the prevention of disease progression in patients with non-small cell lung cancer[R]. Presented at the joint 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology, Berlin, Germany, September 20-24, 2009.